Payment overview · 2025
General Payments
$415.40
9 reported records · 5 companies
Healthcare provider profile · identity verified
Babu Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BRONX, NY · NPI 1689654220
Verified facts
What the public records show
CMS Open Payments records show Babu Patel, MD received $415.40 in general payments during 2025 across 9 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 30.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $125.00 | 30.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $125.00 | 30.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.16 | 23.1% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.06 | 8.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.18 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $415.40 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $96.16 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $96.16 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $35.06 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
90 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1083 | 226 |
| Amlodipine Besylate | Amlodipine Besylate | 861 | 158 |
| Omeprazole | Omeprazole | 756 | 123 |
| Losartan Potassium | Losartan Potassium | 741 | 158 |
| Metoprolol Succinate | Metoprolol Succinate | 637 | 119 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 592 | 103 |
| Naproxen | Naproxen | 548 | 117 |
| Metformin Hcl | Metformin Hcl | 511 | 96 |
| Famotidine | Famotidine | 456 | 87 |
| Ibuprofen | Ibuprofen | 423 | 91 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 410 | 64 |
| Lisinopril | Lisinopril | 353 | 70 |
| Simvastatin | Simvastatin | 319 | 58 |
| Meclizine Hcl | Meclizine Hcl | 306 | 63 |
| Alendronate Sodium | Alendronate Sodium | 305 | 54 |
| Januvia | Sitagliptin Phosphate | 300 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 297 | 62 |
| Meloxicam | Meloxicam | 295 | 58 |
| Diclofenac Sodium | Diclofenac Sodium | 288 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 288 | 51 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 284 | 59 |
| Lovastatin | Lovastatin | 265 | 49 |
| Ammonium Lactate | Ammonium Lactate | 260 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 250 | 58 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 250 | 39 |
| Mirtazapine | Mirtazapine | 245 | 41 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 239 | 75 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 233 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 52 |
| Montelukast Sodium | Montelukast Sodium | 218 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 213 | 38 |
| Sertraline Hcl | Sertraline Hcl | 210 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 197 | 42 |
| Gabapentin | Gabapentin | 193 | 42 |
| Azithromycin | Azithromycin | 186 | 133 |
| Eliquis | Apixaban | 182 | 30 |
| Glipizide Er | Glipizide | 178 | 35 |
| Metformin Hcl Er | Metformin Hcl | 172 | 40 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 161 | 30 |
| Furosemide | Furosemide | 155 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 153 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 144 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 143 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 26 |
| Nifedipine Er | Nifedipine | 119 | 22 |
| Donepezil Hcl | Donepezil Hcl | 112 | 23 |
| Cromolyn Sodium | Cromolyn Sodium | 110 | 18 |
| Azelastine Hcl | Azelastine Hcl | 108 | 27 |
| Farxiga | Dapagliflozin Propanediol | 105 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 103 | 38 |
| Atenolol | Atenolol | 96 | 20 |
| Carvedilol | Carvedilol | 96 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 95 | 16 |
| Trazodone Hcl | Trazodone Hcl | 94 | 19 |
| Ozempic | Semaglutide | 90 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 86 | 58 |
| Betamethasone Valerate | Betamethasone Valerate | 85 | 17 |
| Single Use Swab | Alcohol Antiseptic Pads | 84 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 17 |
| Procto-Med Hc | Hydrocortisone | 75 | 21 |
| Amoxicillin | Amoxicillin | 73 | 52 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 71 | 11 |
| Trulicity | Dulaglutide | 69 | 11 |
| Finasteride | Finasteride | 68 | 13 |
| Novolog Flexpen | Insulin Aspart | 68 | suppressed |
| Prednisone | Prednisone | 68 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 68 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 64 | 16 |
| Nabumetone | Nabumetone | 60 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 60 | 14 |
| Entresto | Sacubitril/Valsartan | 55 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 54 | suppressed |
| Jardiance | Empagliflozin | 54 | 11 |
| Spironolactone | Spironolactone | 52 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 51 | suppressed |
| Hydrocortisone | Hydrocortisone | 50 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | suppressed |
| Potassium Chloride | Potassium Chloride | 49 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 49 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | suppressed |
| Nystatin | Nystatin | 48 | 13 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 47 | 13 |
| Folic Acid | Folic Acid | 47 | suppressed |
| Levetiracetam | Levetiracetam | 47 | 12 |
| Restasis | Cyclosporine | 46 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 43 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 43 | suppressed |
| Methylprednisolone | Methylprednisolone | 43 | 19 |
| Valacyclovir | Valacyclovir Hcl | 43 | 12 |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 41 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 41 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 40 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Torsemide | Torsemide | 32 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 31 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Proctozone-Hc | Hydrocortisone | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Clotrimazole | Clotrimazole | 27 | suppressed |
| Fluocinonide | Fluocinonide | 27 | suppressed |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Ibu | Ibuprofen | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Terconazole | Terconazole | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Letrozole | Letrozole | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Hydrocortisone Valerate | Hydrocortisone Valerate | 18 | suppressed |
| Nexium | Esomeprazole Magnesium | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Apri | Desogestrel-Ethinyl Estradiol | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $415.40 · 9 records | Otsuka America Pharmaceutical, Inc. | Cologuard Collection Kit, Ozempic, REXULTI, Rybelsus, VOQUEZNA, YUPELRI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error